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Background: The GOLD 2011 document proposed a new classification system for COPD combining symptom
assessment by COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores, and
exacerbation risk. We postulated that classification of COPD would be different by the symptom scale; CAT vs
mMRC.
Methods: Outpatients with COPD were enrolled from January to June in 2012. The patients were categorized into
A, B, C, and D according to the GOLD 2011; patients were categorized twice with mMRC and CAT score for
symptom assessment, respectively. Additionally, correlations between mMRC scores and each item of CAT scores
were analyzed.
Results: Classification of 257 patients using the CAT score vs mMRC scale was as follows. By using CAT score, 60
(23.3%) patients were assigned to group A, 55 (21.4%) to group B, 21 (8.2%) to group C, and 121 (47.1%) to group
D. On the basis of the mMRC scale, 97 (37.7%) patients were assigned to group A, 18 (7.0%) to group B, 62 (24.1%)
to group C, and 80 (31.1%) to group D. The kappa of agreement for the GOLD groups classified by CAT and mMRC
was 0.510. The mMRC score displayed a wide range of correlation with each CAT item (r = 0.290 for sputum item to
r = 0.731 for dyspnea item, p < 0.001).
Conclusions: The classification of COPD produced by the mMRC or CAT score was not identical. Care should be
taken when stratifying COPD patients with one symptom scale versus another according to the GOLD 2011
document.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation [1]. The degree
of airflow limitation is associated with many disease out-
comes but was poorly predictive of dyspnea and quality
of life [2-4]. Lung function alone does not explain the
heterogeneous features of COPD [5,6]. Therefore, the
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reproduction in any medium, provided the or(GOLD) 2011 document proposed a new classification
system for COPD, combining symptom assessment and
exacerbation risk including spirometry to identify disease
severity [1].
For assessing symptoms, GOLD 2011 primarily recom-
mends the use of the Modified.
British Medical Research Council (mMRC) question-
naire or the COPD Assessment Test (CAT). The mMRC
scale is a 5-point (0–4) scale based on the severity of
dyspnea [7]. The CAT comprises eight items relating to
the severity of cough, sputum, dyspnea, chest tightness,
capacity for exercise and activities, confidence, sleep. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Kim et al. BMC Pulmonary Medicine 2013, 13:35 Page 2 of 5
http://www.biomedcentral.com/1471-2466/13/35quality and energy levels [8] while mMRC scale is a
quantitative assessment tool only for breathlessness.
These questionnaires are used to distinguish patients
with less severe symptoms from patients with more
severe symptoms; low vs high symptoms in the new
GOLD 2011. However, a recent report indicated that
group assignment of COPD patients could be different
by the symptom scale that is used [9]; Han ML et al.
used mMRC and SGRQ scores (as a surrogate of CAT
scores) for assessing symptoms of COPD. The group
assignment of COPD patients by mMRC vs SGRQ was
not identical [9].
Hence, this study was performed to see whether the
classification of COPD group according to GOLD 2011
would be identical irrespective of symptom scales
(mMRC vs CAT score), and to evaluate the associations
between two symptom scales.
Methods
Subjects
Patients were recruited at outpatient clinics from the de-
partment of pulmonology, Chonnam National University
hospital in South Korea. The flow chart for selecting
patients is shown in Figure 1. All consecutive patients of
the clinic were screened for eligibility from Jan to June,
2012 if they were aged 45–85 years. Patients must also
have had the ability to undertake spirometry and answer
to the questionnaire; CAT and mMRC. Those with









Screened for eligibility 
(age 45-85 years)
(n = 626)
Figure 1 Consort diagram of the study participants. * Airflow obstructi
FEV1/FVC (forced expiratory volume in 1s/forced vital capacity) ratio < 0.70.bronchiectasis and interstitial lung disease were ex-
cluded. COPD was defined according to the GOLD cri-
teria [1]: a postbronchodilator FEV1/FVC (forced
expiratory volume in 1s/forced vital capacity) ratio
below 0.70. Among 378 patients who responded the
questionnaires and met the eligibility requirements, 121
subjects did not have airflow obstruction as defined by
FEV1/FVC <0.70 and therefore they were excluded in
this study. We analyzed the data from 257 patients with
COPD. This study was approved by the ethics and re-
view boards of Chonnam National University Hospital.
All subjects gave informed consent to the work.
Procedures
Symptoms were quantified with both the mMRC [7] and
the CAT [8] (www.catestonline.org). The mMRC scale
0–4 was developed by the American Thoracic Society as
a modification of the originally proposed British Medical
Research Council dyspnea index (scale 1–5) [10]. The
CAT consists of 8 items. Each item is scored from 0 to
5. An overall score is calculated by adding the score
from each item; a total score ranging from 0 to 40. We
determined the distribution of COPD patients with the
mMRC and with the CAT. According to the GOLD
2011 classification [1], patients were stratified with either
mMRC score (0–1 vs ≥2) or CAT score (<10 or ≥10)
resulting in two low-symptom categories (A and C) and
two high-symptom categories (B and D). Exacerbation
risk was assessed with either FEV1% predicted (<50% orExcluded (n = 248)
able to do spirometry (n = 93)
able to read CAT questionaire (n = 32)
tive respiratory disorder  (such as pneumonia, diffuse 
nchiectasis, interstitial lung disease etc.) (n = 78)
clined to participate (n = 45)
Excluded (n = 121)
• No airflow obstruction by GOLD criteria*
on was defined according to the GOLD criteria: a postbronchodilator
Table 1 Clinical characteristics and demographics of
patients (n = 257)
Characteristics* Mean or number of patients SD or %
Age (years) 67.4 9.4
Sex (M:F), n 203:54 79%:21%
BMI 22.7 4.1
Smoking status
ever smoker, n 182 70.8%
never smoker, n 75 29.2%
FEV1, % predicted 74.6 24.8
FEV1 ≥ 50%, n 207 80.5%
FEV1 < 50%. n 50 19.5%
FEV1/FVC 0.56 0.12
Frequent exacerbator, n 132 51.4%
mMRC scores 1.5 1.1
CAT, total 15.7 9.3
*Values presented as mean (S.D.) unless otherwise indicated.
Abbreviation: CAT COPD Assessment Test, mMRC modified Medical Research
Council, BMI Body Mass Index (kg/m2), FEV1 Forced expiratory volume in
1 second, FVC Forced vital capacity.
Table 2 Classifications of COPD groups using mMRC
scores (n = 257)
High risk 62 (24.1%) 80 (31.1%)
Low risk 97 (37.7%) 18 (7.0%)
mMRC 0-1 mMRC ≥ 2
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the previous year to stratify patients into low-risk
groups (A and B) versus high-risk groups(C and D). An
exacerbation was defined as an acute event characterized
by a worsening of the patient’s respiratory symptoms that
is beyond normal day to day variations and leads to a
change in medication [1,11]. The number of exacerbations
in the previous year was taken from patients’ history at the
same time when mMRC and CAT score were measured.
Patients underwent standardized spirometry before and
after the inhalation of 10 mg of salbutamol by nebulizer
[12]. Finally, the patients with COPD were categorized
into A, B, C, and D combining symptom assessment by
COPD assessment test (CAT) or modified Medical Re-
search Council (mMRC) dyspnea scores, and exacerbation
risk according to the 2011 GOLD report.
Statistical analyses
All statistical analyses were done with IBM SPSS Win-
dows version 20.0. All data are presented as mean (SD)
where appropriate. Kappa coefficient is used to interpret
the extent of agreement between two symptom scales
(mMRC vs CAT). The discussion of agreement in this
study is based on kappa value as described previously in
the literature in which k < 0.00 is “poor,” 0 < k < 0.02 is
“slight,” 0.21 < k < 0.40 is “fair,” 0.41 < k < 0.60 is “moderate,”
0.61 < k < 0.80 is “substantial,” 0.81 < k < 1.00 is “almost
perfect”, and k = 1 is “perfect” agreement [13]. The
correlation between mMRC dyspnea score and CAT score
was examined using the Spearman rank correlation coeffi-
cient (rho), because the MRC dyspnea score is an ordinal
categorical variable. Differences were considered statisti-
cally significant when p < 0.05.
Results
From January to June in 2012, 257 patients with COPD
completed the questionnaire; CAT and mMRC dyspnea
scale. Characteristics of subjects (mean age 67.4 ± 9.4 years;
203 men, 54 women) are summarized in Table 1. The
mean body mass index (BMI) was 22.7 kg/m2. The major-
ity of subjects were cigarette smokers (n = 182, 70.8%).
Fifty subjects (19.5%) were high risks based on GOLD’s
spirometric criteria (FEV1 < 50%), and 132 (51.4%) sub-
jects were high risk according to the number of exacerba-
tions of COPD (≥2 exacerbations in the previous year).
Mean mMRC and CAT scores were 1.5 and 15.7,
respectively.
Group assignments using the mMRC scale and CAT
score were shown in Table 2 and 3. Among 257 COPD
patients, using mMRC scale (Table 2), 97 (37.7%) patients
were assigned to group A, 18 (7.0%) to group B, 62
(24.1%) to group C, and 80 (31.1%) to group D; on the
basis of the CAT score (Table 3), 60 (23.3%) patients were
assigned to group A, 55 (21.4%) to group B, 21 (8.2%) togroup C, and 121 (47.1%) to group D. When the stratifica-
tion of symptom group was done by CAT scores, the
proportion of high symptom groups was increased. The
kappa of agreement for the GOLD groups by CAT and
mMRC was 0.510, suggesting moderate not substantial
agreement. To investigate why symptoms groups were not
identical between CAT and mMRC, we displayed the
distributions of total CAT scores that were stratified into
four groups at every mMRC level (Table 4). Within each
mMRC level, there was a wide heterogeneous distribution
of CAT scores. The mMRC score of 2 corresponded with
a mean CAT score of 21 (SD 8), whereas the mMRC score
of 1 corresponded to a mean CAT score of 13 (SD 6).
The correlations between mMRC scores and each
CAT item were shown in Table 5. The mMRC scores
displayed a wide range of correlation with each CAT
item (r = 0.290 ~ 0.731; p < 0.0001). Of the CAT items,
the dyspnea item had the strongest correlation with the
mMRC scores (r = 0.731, p < 0.001). However, the correl-
ation between mMRC and the item of sputum in CAT
was not strong (r = 0.290, p < 0.001).
Table 3 Classifications of COPD groups using CAT scores
(n = 257)
High risk 21 (8.2%) 121 (47.1%)
Low risk 60(23.3%) 55(21.4%)
CAT < 10 CAT≥ 10
Table 5 Correlations between mMRC and each item of
CAT scores
mMRC
Spearman’s rho P value
Each item of CAT Cough .310** <.0001
sputum .290** <.0001




Sleep quality .381** <.0001
Energy level .526** <.0001
**Correlation is significant at the <0.01 level.
Kim et al. BMC Pulmonary Medicine 2013, 13:35 Page 4 of 5
http://www.biomedcentral.com/1471-2466/13/35Discussion
A main finding of this study was that the group classifi-
cation of COPD produced by each symptom scale was
not identical because the distributions of CAT scores
were heterogeneous at every mMRC level. The group
classification is important because treatment is re-
commended according to the groups of COPD in the
2011 GOLD.
The mMRC scale is widely used to measure breath-
lessness because of brevity and simplicity [7]. However,
it is a unidimensional measurement to quantify only dys-
pnea. The CAT score is a multidimensional method,
which assess 8 items; not only dyspnea but also other
symptoms and health status [8,14]. It has proposed as a
new tool for assessment of COPD health status in daily
practice since it has the advantage of being easy to per-
form and it can be associated with clinically important
variables (FEV1%, exacerbation as well as MRC dys-
pnea scale) [15,16]. And, the CAT has good repeatabil-
ity [17] and is responsive to exacerbation onset and
recovery [18].
GOLD 2011 recommends the CAT or mMRC scores
to distinguish the symptom groups (high vs low symp-
toms). And, GOLD mentioned that it is unnecessary to
use more than one symptom scale. However, a wide
range of CAT scores was seen at each mMRC score in
our study. The group assignment of COPD patients by
each symptom scale was different. As the symptomatic
cutpoint to differentiate the symptom groups, GOLD
proposed either CAT score of 10 or mMRC score of 2.
But, this study showed that an mMRC of 2 did not
correspond with a CAT of 10. An mMRC of 1 wasTable 4 Distributions of CAT total scores at each mMRC
level (n = 257)
mMRC
0 1 2 3 4
CAT total scores 0–9 Count 37 38 5 2 0
% of Total 14.4% 14.8% 1.9% .8% 0.0%
10–19 Count 12 53 12 11 1
% of Total 4.7% 20.6% 4.7% 4.3% 0.4%
20–29 Count 2 18 14 23 7
% of Total 0.8% 7.0% 5.4% 8.9% 2.7%
30–40 Count 0 0 8 12 2
% of Total 0.0% 0.0% 3.1% 4.7% 0.8%comparable to a CAT of 10. These results support a re-
cent report [9] Han et al. used St George’s Respiratory
Questionnaire (SGRQ) score as a surrogate for the CAT
score to assess symptoms. The choice of symptom meas-
ure influenced category assignment of COPD. And, the
mMRC score of 1 corresponded with an SGRQ of 25
that is similar with a CAT score of 10 [9].
The above findings suggest that refinement for differ-
entiating symptom groups would be needed. The one re-
finement method is the change of cutpoint for mMRC
from 2 to 1 because an mMRC of 1 corresponds to a
CAT of 10. When the patients of our study were strati-
fied using mMRC ≥1 as the symptomatic cutpoint, the
kappa agreement between the groups by mMRC and
CAT was more improved 0.510 into 0.649 (Table 6).
However, the agreement between them was not perfect.
This suggests that patients classified by the two symp-
tom metrics will not be identical irrespective of changes
of symptom’s cutpoint. This can be also supported by
Han et al.’s report [9]. Another potential refinement
method is as follows: To stratify symptom groups in
COPD, both CAT and mMRC should be measured rou-
tinely. Then, symptom group would be determined by
symptom scales showing the higher score like assess-
ment of exacerbation risk using FEV1 and previous
exacerbation history. This method can be considered in
the future revision of COPD stratification. However, the
different categories for both symptom and exacerbation
assessment could be more demanding without treatment
consequences. This issue also should be further studiedTable 6 Classifications of COPD groups using mMRC
scores (cutpoint of mMRC = 1)* (n = 257)
High risk 9 (3.5%) 133(51.8%)
Low risk 41 (16.0%) 74(28.8%)
mMRC < 1 mMRC ≥ 1
*Kappa agreement with COPD groups classified by CAT scores was 0.649.
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ment of COPD.
Secondary finding of this study is that all of each CAT
item was found to have significant correlations with
mMRC scores. However, it had a wide range of correl-
ation coefficients. The mMRC score is the most strongly
correlated with dyspnea item of CAT while the correla-
tions of mMRC with other items of CAT were less
strong. This is not a surprising result since mMRC is an
indicator of breathlessness. Also, this could suggest that
mMRC scale only for breathlessness cannot be identical
with CAT score and it cannot be used as a surrogate of
CAT score.
We acknowledge a major limitation of this study. The
subjects were the patients who referred from primary
clinics and were recruited from a single center. Our re-
sults, however, are comparable with a recent, multicen-
ter study. An advantage of this study is that the mMRC
and CAT were compared directly regarding to the recent
GOLD report. The other weakness of this study is that
the prospective analysis of exacerbation was not in-
cluded. A prospective study will be needed to explore
the clinical impacts of stratification of COPD on future
exacerbations and treatments in patients with COPD.
Conclusions
In conclusion, the GOLD 2011 recommends the use of
mMRC or CAT scores for assessing symptoms. However,
we showed that choice of symptom scale can alter group
assignment of COPD because mMRC and CAT do not
behave identically in distinguishing symptom groups. A
refinement of the GOLD classification should be consid-
ered in the future.
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